Oseltamivir pharmacokinetics, dosing, and resistance among children aged <2 years with influenza.
J Infect Dis
; 207(5): 709-20, 2013 Mar 01.
Article
de En
| MEDLINE
| ID: mdl-23230059
ABSTRACT
BACKGROUND:
Children <2 years of age are at high risk of influenza-related mortality and morbidity. However, the appropriate dose of oseltamivir for children <2 years of age is unknown.METHODS:
The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group evaluated oseltamivir in infants aged <2 years in an age-de-escalation, adaptive design with a targeted systemic exposure.RESULTS:
From 2006 to 2010, 87 subjects enrolled. An oseltamivir dose of 3.0 mg/kg produced drug exposures within the target range in subjects 0-8 months of age, although there was a greater degree of variability in infants <3 months of age. In subjects 9-11 months of age, a dose of 3.5 mg/kg produced drug exposures within the target range. Six of 10 subjects aged 12-23 months receiving the Food and Drug Administration-approved unit dose for this age group (ie, 30 mg) had oseltamivir carboxylate exposures below the target range. Virus from 3 subjects developed oseltamivir resistance during antiviral treatment.CONCLUSIONS:
The appropriate twice-daily oral oseltamivir dose for infants ≤8 months of age is 3.0 mg/kg, while the dose for infants 9-11 months old is 3.5 mg/kg.
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Orthomyxoviridae
/
Résistance virale aux médicaments
/
Grippe humaine
/
Oséltamivir
Limites:
Female
/
Humans
/
Infant
/
Male
/
Newborn
Langue:
En
Journal:
J Infect Dis
Année:
2013
Type de document:
Article
Pays d'affiliation:
États-Unis d'Amérique